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Abstract 
 
Background: Medication non-adherence is a global issue of major public health 
concern highlighted by the causal link between non-adherence, increased disease 
prevalence and health care resource use. Cost assessment of the economic burden 
lacks uniformity and consistency in determination. The use of a standardised 
methodology to determine the cost associated with medication non-adherence is 
required to facilitate international comparisons and demonstrate a reliable estimate 
of the magnitude of the problem on a global scale.   
Objectives: To explore, analyse and estimate the economic impact of medication 
non-adherence.  The research aimed to conceptualise and define a cost estimation 
framework to streamline the cost outcome indicators that are employed to evaluate 
the monetary burden linked to non-adherence. Additionally, a monetary estimate of 
the medication non-adherence burden in Australia was quantified whilst 
simultaneously exploring the potential role community pharmacists play in reducing 
the associated burden.  
Methodology: A series of discrete studies were undertaken: (1) a systematic review 
of studies assessing the economic impact of medication non-adherence across 
disease groups; (2) development of a medication adherence cost estimation (MACE) 
framework through secondary analysis of the systematic review data; and (3) analysis 
of a large database of patient dispensing records appraising the cost of medication 
non-adherence in Australia and the cost saving effect community pharmacist led 
intervention had on adherence. 
Results: The systematic review identified wide scoping cost variations reported 
across 79 studies, with lower levels of adherence associated with higher health care 
costs. Annual adjusted disease specific economic cost of non-adherence per person 
ranged from USD2015 $949- $44190 (chapter 3). Collation of outcomes resulted in 
the development of the MACE framework through identification of two core cost 
outcome indicators (direct and indirect costs), seven subcategories (hospital, primary 
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care, medical test, pharmacy, direct non-medical, societal and productivity costs) and 
35 cost outcome indicator examples. The most utilised cost categories were hospital 
(68%, n=54), primary care (18%, n=15) and pharmacy costs (72%, n=57) (chapter 4). 
The national cost of medication non-adherence in Australia across hypertension, 
dyslipidaemia and depression was AUD2018 $10.4 billion. Community pharmacist led 
intervention was estimated to save the Australian health care system AUD2018 $1.9 
billion annually. Application of the MACE framework post pharmacist intervention 
highlighted the greatest cost contributors to be associated with direct costs, 
particularly, outpatient expenses $2.1 billion, inpatient admissions $1.9 billion, 
prescription medications $1.8 billion and medical related expenses $1.6 billion 
(chapter 5).       
Conclusion: Medication non-adherence is a costly burden placing financial drain on 
health care systems that has failed to be adequately prioritised by governments and 
health care organisations within national policy. The incorporated framework has 
been proposed to homogenise international measures and applied to the Australian 
landscape to demonstrate the scope of the problem and highlight the potential role 
of community pharmacists moving forward to counteract the rising economic 
encumbrance. The MACE framework facilitates the strengthening of adherence 
research and provides a strong foundation for evidence based costing studies to be 
incorporated into economic evaluations to aid decision making. Decision makers 
should seek to utilise pharmacists as an integrated member of the health care team 
to help curb the rising burden of medication non-adherence and generate cost 
savings to the health care system.   
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Preface 
 
This thesis is presented in fulfilment of the doctoral degree (Doctor of Philosophy) 
requirements of the University of Technology Sydney, Australia.  
The thesis is structured as a PhD by compilation. Chapter 1 contains a research 
overview and general disposition of the thesis. An outline of the overall rationale, 
objectives and organisation of the thesis is included. Chapter 2 provides the 
background and reasoning for the topic. Chapters 3-5 comprise the sequential results 
including a systematic review outlining the economic impact of medication non-
adherence across disease groups, development of the medication adherence cost 
estimation framework and a national estimate of the cost of medication non-
adherence in Australia. The chapters have been structured as research articles 
containing all corresponding references, figures, tables and appendices related to the 
research activity.  This is followed by Chapter 6, which discusses the results, 
summarises the contribution of work and provides recommendations for future 
research.  
Rachelle L. Cutler is the primary author of each publication. Additionally, co-authors 
contributed to the conception or design of the work, data collection, data analysis 
and interpretation, or revision of the manuscripts.   
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